JP2017509633A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509633A5 JP2017509633A5 JP2016557276A JP2016557276A JP2017509633A5 JP 2017509633 A5 JP2017509633 A5 JP 2017509633A5 JP 2016557276 A JP2016557276 A JP 2016557276A JP 2016557276 A JP2016557276 A JP 2016557276A JP 2017509633 A5 JP2017509633 A5 JP 2017509633A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- polypeptide
- acid sequence
- mk2i
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 48
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 229940124789 MK2 inhibitor Drugs 0.000 claims description 34
- 230000001225 therapeutic effect Effects 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 18
- 230000002159 abnormal effect Effects 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 14
- 206010010187 Complications of transplanted lung Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 12
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 12
- 210000002950 fibroblast Anatomy 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 11
- 230000008021 deposition Effects 0.000 claims description 10
- 210000002744 extracellular matrix Anatomy 0.000 claims description 10
- 230000035755 proliferation Effects 0.000 claims description 10
- 101710092489 Protein kinase 2 Proteins 0.000 claims description 8
- 229940112141 dry powder inhaler Drugs 0.000 claims description 8
- 229940071648 metered dose inhaler Drugs 0.000 claims description 8
- 230000002297 mitogenic effect Effects 0.000 claims description 8
- 239000006199 nebulizer Substances 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 7
- 102000004889 Interleukin-6 Human genes 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 102000001253 Protein Kinase Human genes 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 210000000651 myofibroblast Anatomy 0.000 claims description 6
- 108060006633 protein kinase Proteins 0.000 claims description 6
- 230000009885 systemic effect Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 208000034706 Graft dysfunction Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 229940100601 interleukin-6 Drugs 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 102000007469 Actins Human genes 0.000 claims description 2
- 108010085238 Actins Proteins 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 208000004530 Primary Graft Dysfunction Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 230000009545 invasion Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 230000036470 plasma concentration Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 230000004071 biological effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 206010060872 Transplant failure Diseases 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953438P | 2014-03-14 | 2014-03-14 | |
| US61/953,438 | 2014-03-14 | ||
| PCT/US2015/020263 WO2015138784A2 (en) | 2014-03-14 | 2015-03-12 | Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509633A JP2017509633A (ja) | 2017-04-06 |
| JP2017509633A5 true JP2017509633A5 (enExample) | 2018-04-19 |
| JP6655547B2 JP6655547B2 (ja) | 2020-02-26 |
Family
ID=54067793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016557276A Expired - Fee Related JP6655547B2 (ja) | 2014-03-14 | 2015-03-12 | 慢性肺移植片機能不全（ｃｌａｄ）および特発性肺線維症（ｉｐｆ）を予防または処置するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150258192A1 (enExample) |
| EP (1) | EP3116543A4 (enExample) |
| JP (1) | JP6655547B2 (enExample) |
| KR (1) | KR20160124236A (enExample) |
| CN (1) | CN106456758A (enExample) |
| AU (1) | AU2015229251A1 (enExample) |
| BR (1) | BR112016021000A2 (enExample) |
| CA (1) | CA2942517A1 (enExample) |
| MX (1) | MX2016011852A (enExample) |
| RU (1) | RU2016140332A (enExample) |
| SG (1) | SG11201607627RA (enExample) |
| WO (1) | WO2015138784A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3352792B1 (en) * | 2015-09-25 | 2020-08-26 | Cedars-Sinai Medical Center | Targeting fibroblast invasion for pulmonary fibrosis |
| WO2019070908A1 (en) | 2017-10-03 | 2019-04-11 | Cedars-Sinai Medical Center | METHODS OF TARGETING THE PD1 PATHWAY OF THE IMMUNE CONTROL POINT FOR THE TREATMENT OF PULMONARY FIBROSIS |
| CN113906132B (zh) * | 2019-05-30 | 2024-06-28 | 北京生命科学研究所 | 特发性肺纤维化的动物模型、其构建方法和用途 |
| KR20230044446A (ko) * | 2020-07-24 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 급성 호흡기 장애의 치료 방법 |
| CN112575074B (zh) * | 2020-10-09 | 2022-12-27 | 中山大学 | Nestin基因及蛋白在治疗器官纤维化中的应用 |
| WO2022147172A1 (en) * | 2020-12-30 | 2022-07-07 | Briotech, Inc. | Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1727564A1 (en) * | 2004-03-17 | 2006-12-06 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Cd44-targeting for reducing/preventing ischemia-reperfusion-injury |
| US7723336B2 (en) * | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20080199426A1 (en) * | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
| WO2012142238A2 (en) * | 2011-04-12 | 2012-10-18 | Duke University | Compositions and methods for the treatment of tissue fibrosis |
| ES2711670T3 (es) * | 2011-04-12 | 2019-05-06 | Moerae Matrix Inc | Composiciones y métodos para la prevención o tratamiento de la fibrosis pulmonar |
-
2015
- 2015-03-12 MX MX2016011852A patent/MX2016011852A/es unknown
- 2015-03-12 SG SG11201607627RA patent/SG11201607627RA/en unknown
- 2015-03-12 JP JP2016557276A patent/JP6655547B2/ja not_active Expired - Fee Related
- 2015-03-12 CN CN201580025482.9A patent/CN106456758A/zh active Pending
- 2015-03-12 RU RU2016140332A patent/RU2016140332A/ru not_active Application Discontinuation
- 2015-03-12 EP EP15761995.8A patent/EP3116543A4/en not_active Withdrawn
- 2015-03-12 KR KR1020167028395A patent/KR20160124236A/ko not_active Withdrawn
- 2015-03-12 BR BR112016021000A patent/BR112016021000A2/pt not_active Application Discontinuation
- 2015-03-12 US US14/656,492 patent/US20150258192A1/en not_active Abandoned
- 2015-03-12 AU AU2015229251A patent/AU2015229251A1/en not_active Abandoned
- 2015-03-12 WO PCT/US2015/020263 patent/WO2015138784A2/en not_active Ceased
- 2015-03-12 CA CA2942517A patent/CA2942517A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509633A5 (enExample) | ||
| RU2013150249A (ru) | Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса | |
| JP2014533235A5 (enExample) | ||
| FI106433B (fi) | Menetelmä farmaseuttisen formulaation valmistamiseksi, joka soveltuu granulosyyttipesäkkeitä stimuloivan tekijän antamiseen keuhkojen kautta | |
| US10927166B2 (en) | Compositions comprising an anti-C5 antibody | |
| Lim et al. | Reduced peribronchial fibrosis in allergen-challenged MMP-9-deficient mice | |
| JP2016516016A5 (enExample) | ||
| JP2014515763A5 (enExample) | ||
| CN102596216B (zh) | 鼻炎治疗剂 | |
| Atzeni et al. | Interleukin 6 blockade: tocilizumab in psoriatic arthritis | |
| JP2018501201A5 (enExample) | ||
| JP2015505303A5 (enExample) | ||
| RU2016140332A (ru) | Композиции и способы предотвращения или лечения хронической дисфункции аллотрансплантата легкого (хдал) и идиопатического фиброза легких (ифл) | |
| Banaszczyk | Risankizumab in the treatment of psoriasis–literature review | |
| Zhang et al. | Therapeutic efficacy of a co-blockade of IL-13 and IL-25 on airway inflammation and remodeling in a mouse model of asthma | |
| Li et al. | CpG-ODNs and budesonide act synergistically to improve allergic responses in combined allergic rhinitis and asthma syndrome induced by chronic exposure to ovalbumin by modulating the TSLP-DC-OX40L axis | |
| JP2017528454A5 (enExample) | ||
| RU2017110093A (ru) | Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса | |
| Niina et al. | A sustained prostacyclin analog, ONO-1301, attenuates pancreatic fibrosis in experimental chronic pancreatitis induced by dibutyltin dichloride in rats | |
| Hong et al. | Effect of substance P on recovery from laser‐induced retinal degeneration | |
| EP3541402B1 (en) | C3a receptor agonists for use against ischemic brain injury | |
| Marzoog | Pulmonary fibrosis; risk factors and molecular triggers, insight for neo therapeutic approach | |
| Perretti et al. | Cytokines, glucocorticoids and lipocortins in the control of neutrophil migration | |
| CN104138391A (zh) | 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用 | |
| Wang et al. | The effects of aerosolized STAT1 antisense oligodeoxynucleotides on rat pulmonary fibrosis |